Virtus ETF Advisers LLC Apellis Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

$234 Million
Q4 2024

A detailed history of Virtus ETF Advisers LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 10,680 shares of APLS stock, worth $292,632. This represents 0.15% of its overall portfolio holdings.

Number of Shares

10,680

Previous 7,738 38.02%

Holding current value

$292,632

Previous $223,000 52.47%

% of portfolio

0.15%

Previous 0.11%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $77,021 - $104,205	2,942 Added 38.02%	10,680 $340,000
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $16,598 - $26,033	436 Added 5.97%	7,738 $296,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $58,214 - $76,165	1,051 Added 16.81%	7,302 $429,000
Q4 2023 Feb 15, 2024	BUY	$37.14 - $64.82 $109,563 - $191,218	2,950 Added 89.37%	6,251 $374,000
Q3 2023 Nov 07, 2023	SELL	$23.65 - $89.22 $10,145 - $38,275	-429 Reduced 11.5%	3,301 $125,000
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $162,331 - $197,537	-2,117 Reduced 36.21%	3,730 $339,000
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $4,845 - $6,963	104 Added 1.81%	5,847 $385,000
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $13,534 - $19,105	-313 Reduced 5.17%	5,743 $296,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3,849 - $5,990	86 Added 1.44%	6,056 $414,000
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $96,617 - $163,123	-2,755 Reduced 31.58%	5,970 $270,000
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $51,428 - $82,244	1,673 Added 23.72%	8,725 $413,000
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $20,127 - $44,767	-641 Reduced 8.33%	7,052 $232,000
Q2 2021 Aug 10, 2021	BUY	$40.9 - $64.9 $79,018 - $125,386	1,932 Added 33.54%	7,693 $486,000
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $3,794 - $5,337	93 Added 1.64%	5,761 $247,000
Q4 2020 Feb 12, 2021	SELL	$30.79 - $57.2 $131,750 - $244,758	-4,279 Reduced 43.02%	5,668 $324,000
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $35,003 - $45,494	-1,352 Reduced 11.97%	9,947 $300,000
Q2 2020 Aug 05, 2020	SELL	$24.8 - $38.49 $42,085 - $65,317	-1,697 Reduced 13.06%	11,299 $369,000
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $33,885 - $83,872	-1,892 Reduced 12.71%	12,996 $348,000
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $65,261 - $90,952	2,953 Added 24.74%	14,888 $456,000
Q3 2019 Nov 12, 2019	SELL	$24.09 - $32.18 $16,019 - $21,399	-665 Reduced 5.28%	11,935 $288,000
Q2 2019 Aug 13, 2019	SELL	$18.0 - $25.34 $31,284 - $44,040	-1,738 Reduced 12.12%	12,600 $319,000
Q1 2019 May 14, 2019	SELL	$12.81 - $19.82 $20,086 - $31,077	-1,568 Reduced 9.86%	14,338 $280,000
Q4 2018 Feb 05, 2019	SELL	$11.47 - $18.71 $57,223 - $93,344	-4,989 Reduced 23.88%	15,906 $210,000
Q3 2018 Nov 14, 2018	SELL	$16.57 - $21.03 $253,984 - $322,347	-15,328 Reduced 42.32%	20,895 $372,000
Q2 2018 Aug 10, 2018	BUY	$19.63 - $30.0 $711,057 - $1.09 Million	36,223 New	36,223 $797,000

Others Institutions Holding APLS

# of Institutions

304

Shares Held

117M

Call Options Held

3.03M

Put Options Held

1.05M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.01B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Apellis Pharmaceuticals, Inc. Transaction History